跳至主要内容
临床试验/NCT03192488
NCT03192488已完成4 期

Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia

Indiana University1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2017年8月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
13
试验地点
1
主要终点
Performance Time

研究概览

简要总结

This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec® use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design.

详细描述

This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec® use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design. Non-invasive techniques (pulse oximetry, near-infrared spectroscopy [NIRS]) will be utilized to measure changes in arterial oxyhemoglobin saturation and skeletal muscle oxygenation at the level of the microvasculature during exercise. It is expected that after Cetirizine, blood and muscle microvascular oxygenation during heavy exercise will improve compared to placebo, ultimately improving exercise performance at altitude. Subjects will be asked to report to the laboratory on a three occasions, separated by a minimum of 48 hours and a maximum of 14 days. For each subject, all testing sessions will be performed at the same time of day. Prior to each testing session, subjects will be asked to abstain from caffeine consumption for 12 hours. Subjects will also be asked to avoid alcohol consumption for 24 hours before testing, be at least 3-hour post prandial and avoid high-intensity exercise during the 24 hours leading to the exercise testing. Finally, subjects will be asked to consume a similar diet the night before, and the morning of, Sessions 2 and 3.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Physically active a minimum of 120 minutes a week, as determined by questionnaire
  • 18-35 years of age
  • Classified as low risk, based on the modified PAR-Q questionnaire, BMI, and non-smoking status
  • No history of pulmonary disease and pulmonary function classified as normal, as defined by the following measurements being 80% of predicted values: forced vital capacity (FVC), forced expired volume in one second (FEV1) and FEV1/FVC, according to the American Thoracic Society standards.

排除标准

  • Current smoker
  • Women who are pregnant or could possibly be pregnant
  • BMI > 25 kg/m2
  • A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire
  • History of pulmonary disease or <80% of predicted FCV, FEV1 and/or FEV1/FVC.
  • A history of renal or liver disease, due to possible interaction effect with Cetirizine
  • Currently taking any prescription or over the counter medications for the treatment of allergies, or taking any of the below listed drugs known to have a moderate or higher interaction effect with Cetirizine:
  • isocarboxazid tranylcypromine bosutinib clobazam crizotinib daclatasvir eliglustat hyaluronidase lomitapide lurasidone ombitasvir/paritaprevir/ritonavir phenelzine ponatinib ritonavir vemurafenib

研究组 & 干预措施

Cetirizine/Hypoxia

Experimental

Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).

干预措施: Cetirizine (Drug)

Cetirizine/Hypoxia

Experimental

Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).

干预措施: Hypoxia (Other)

Placebo/Normoxia

Placebo Comparator

Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).

干预措施: Placebo oral capsule (Drug)

Placebo/Hypoxia

Placebo Comparator

Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).

干预措施: Placebo oral capsule (Drug)

Placebo/Hypoxia

Placebo Comparator

Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).

干预措施: Hypoxia (Other)

结局指标

主要结局

Performance Time

时间窗: Performed 60min after pill ingestion

Time to complete 8km cycling time trial

次要结局

  • Plasma Histamine Concentrations at Baseline and Post-Exercise(baseline and immediately post-exercise, same day as pill ingestion)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Robert Chapman

Associate Professor

Indiana University

研究点 (1)

Loading locations...

相似试验